According to Lilly, three of the future US sites will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening its supply chain. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies.

"Lilly's optimism about the potential of our pipeline across therapeutic areas – cardiometabolic health, oncology, immunology and neuroscience – drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the USA," said David A. Ricks, Lilly’s CEO.

At the four new sites, Lilly expects to create more than 3,000 jobs.

"To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations.

The recently announced investments bring the company's total US capital expansion commitments to more than $50 billion since 2020.